ABSTRACT
INTRODUCTION
The concept of transcatheter insertion of heart valves as a treatment option for valvular heart disease has been around since the 1960s [1] . In the 1990s, transcatheter implantation of aortic valves in pig models was described [2] , but it was not until 2000 that Bonhoeffer et al. [3] described the first implantation of a transcatheter pulmonic valve in a human being. The valve was comprised of a fresh bovine jugular vein, containing a native platinum stent. It was implanted in a 12-yearold boy with pulmonic stenosis and a degenerated right ventricle (RV) to pulmonary artery (PA) conduit with RV dysfunction. 2 years following this report, Cribier et al. [4] described the first percutaneous transcatheter implantation of an aortic valve prosthesis in a 57-year-old patient with calcific aortic stenosis. This valve consisted of three equine pericardial leaflets mounted within a tubular, slotted, stainless steel balloon-expandable stent, designed to achieve a diameter of 21-22 mm.
This aortic valve model was the predecessor of the Edwards SAPIEN TM transcatheter heart valve (THV) (Edwards Lifesciences). Over the next decade, the field of transcatheter valve replacement skyrocketed with multiple largescale randomized trials, which ultimately lead to the Edwards SAPIEN THV being the first percutaneous valve approved by the US food and drug administration (FDA) for inoperable patients with calcific aortic valve stenosis [5] . In this paper, the authors review the history and specifications of the valve, procedural steps for transfemoral insertion of the valve, and detailed results of the Placement of AoRTic TraNscathetER Valve (PARTNER) I trial.
Calcific Aortic Stenosis
Calcific aortic stenosis is a common disease process that is estimated to affect 8-12% of patients over the age of 75 years [6] . It is a progressive disease, and once symptoms develop, deterioration can be quite rapid with a high-level of morbidity and mortality. In symptomatic patients, if left untreated, the 2-year mortality approaches 50% [7, 8] .
Fortunately, in the right patient, surgical aortic valve replacement (AVR) is an excellent option, which leads to symptom resolution and improved mortality [9, 10] . In patients with little or no comorbid conditions, surgery is quite safe and is associated with low operative mortality [11] . However, for a large proportion of patients with severe aortic stenosis (30%), due to multiple comorbid conditions, surgery is not an option [12, 13] .
TRANSCATHETER AVR
Transcatheter AVR (TAVR) was first introduced by Cribier et al. [4] in 2002 with the aim of offering an alternative treatment option for patients with severe symptomatic aortic stenosis who were at high-risk for surgical AVR [14] . Over the last 10 years since its conception, the technique and the devices available have rapidly evolved [15, 16] . Currently, over 50,000
patients have undergone TAVR worldwide [17] , with at least 25,000 of those performed using the Edwards SAPIEN THV.
The Edwards SAPIEN THV
The Edwards SAPIEN THV is made up of three equal-sized bovine pericardial leaflets that are hand-sewn to a stainless steel, balloonexpandable stent (Fig. 1a1, a2) . A polyethylene terephthalate (PET) fabric cuff covers the lower portion of the stent to enable a seal with the calcified valve, hoping to prevent paravalvular leak. The leaflet material has been designed to reduce leaflet stress and maximize coaptation. Fig. 1b, c) . It has a distal cone tip, which helps in advancing the THV across tortuous vessels, reducing friction at the level of the aortic arch, and crossing the native calcified Fig. 1 The Edwards SAPIEN transcatheter heart valve and RetroFlex 3 transfemoral system. The valve (a1 and a2) is available in 23 mm or 26 mm diameter. It consists of three equal-sized bovine pericardial cusps mounted into a stainless-steel balloon expandable stent. The RetroFlex 3 delivery system has a tapered steerable tip (b), which facilitates valve crossing (white arrow indicates the location of the valve on the catheter). The handle of the RetroFlex 3 catheter (c) has a knob (white arrow) to steer the tip of the catheter during aortic arch crossing Fig. 2 The Edwards SAPIEN transcatheter heart valve being crimped on the balloon using a crimping tool. a Stent/valve on delivery balloon. The blue/green suture line on the valve (arrow) should be pointing towards the yellow tip for delivery in the aortic position. b The valve being crimped using the crimping tool (arrow). c Valve (arrow) crimped on the delivery balloon, and covered with the introducer/loader (d) to prevent damage to the valve when advancing it through the sheath The newer model of the Edwards SAPIEN THV, the Edwards SAPIEN XT THV (Edwards Lifesciences LLC; Fig. 3a1, a2) , is mounted on a cobalt-chromium alloy frame and has several advantages over its predecessors. Perhaps most importantly, it has a lower profile (16 Fr 
Patient Selection
Careful patient selection is critically important to ensure a successful procedure. The authors typically use the inclusion and exclusion criteria for the PARTNER I trial, as described in the clinical data section of this paper. As the Edwards SAPIEN THV is only approved for patients who are not surgical candidates, the Fig. 3 The Edwards SAPIEN XT transcatheter heart valve and NovaFlex ? transfemoral system. The valve (a1 and a2) is available in 23 mm or 26 mm in the US, and 29 mm internationally. It consists of three bovine pericardial cusps mounted into a cobalt-chromium balloon expandable stent. b The NovaFlex delivery system has a much smaller tapered yellow tip (white arrow), which facilitates crossing the aortic valve; the black indicates valve position on the catheter when crimped. c1 The handle of the NovaFlex has a large front knob 1 to steer the tip of the catheter. The catheter is advanced inside the sheath where the tip of the catheter is at the crimped valve over the shaft. Once the catheter is in the thoracic/abdominal aorta the locking button 2 is pushed and the balloon catheter is retracted so that the valve straddles the markers on the balloon. Once it is close, then fine adjustments can be made using the back knob 3 until the valve is between the two markers on the balloon. c2 Prior to balloon inflation, one should push the button (arrow) and pull the catheter back off the balloon until it is completely away from the balloon 
PROCEDURAL STEPS

Patient Setup
The authors prefer to perform the procedures in the hybrid catheterization laboratory using reports of coronary occlusion following valve delivery [18, 19] .
Crossing the Valve
After the angiogram has been completed, the [20] and has been an integral part of the TAVR procedure [21] . At this point, prior to BAV, the entire team takes a ''timeout'' to review all the necessary steps/equipment availability in the room in case of an emergency. A nurse who is in charge of the patient calls the timeout and goes over a few points (balloon size to be used, valve size to be 
Valve Delivery
The valve, which has been crimped on the delivery balloon (Fig. 2b) is covered with the loader before insertion into the arterial sheath (Fig. 2d) ; this prevents any damage to the stent.
The valve is then advanced under fluoroscopic guidance. In the aortic arch, moderate flexion of the RetroFlex 3 system will decrease the friction against the wall and reduce the risk of plaque embolization. Once the stent is across the native valve, the RetroFlex 3 catheter is then withdrawn over the balloon catheter shaft without moving the bioprosthesis. This allows for full expansion of the balloon. At this point, the camera should be moved to the angle that was previously determined to profile the annulus best in order to orient the valve calcium perpendicular to the screen. TEE is helpful to determine whether the prosthesis is centered within the native valve (Fig. 4b) , and angiography may be performed through a pigtail catheter from the contralateral artery sitting just above the sinuses (Fig. 5d) . The authors aim to have the valve straddle the annulus in 50/50 (50% over the aortic side and 50% ventricular side) ratio. On occasions, the authors hold respiration and pace the ventricle during this crucial angiogram to determine valve position.
Valve Deployment
The valve is deployed with a manual inflation device that is provided with the valve set. The syringe is filled with 15:85 contrast medium to saline solution, the volume of which has been predetermined in order to obtain an optimal valve diameter. Valve deployment must be done with rapid RV pacing and cardiac standstill. The balloon should remain inflated for at least 3 s (Fig. 5e) . RV pacing should be initiated before balloon inflation and should be terminated after the balloon is completely deflated.
Appropriate valve position is quickly determined by TEE (Fig. 4c) and fluoroscopy ( Fig. 5f, g ). The presence of paravalvular leak is then evaluated by TEE (Fig. 4d) may be recorded at the conclusion of the procedure.
Arterial Hemostasis
As mentioned previously, this is one of the most important steps of the entire procedure. The authors advocate the ''preclose'' technique where two Perclose ProGlide sutures are placed in the 10 o'clock and 2 o'clock positions at the beginning of the case, and the authors use the cross-over technique [22] . Once the procedure is finished (valve deployed and tested) and it is time for hemostasis, the authors insert an exchange length Terumo Glidewire through the contralateral artery, snare it with a 25 mm 
FOLLOW-UP
The patients are generally observed in the coronary care unit for several days to ensure that no vascular complications occur and that the patient fully recovers prior to discharge. cardiac mortality was 19.6% in the TAVR group and 41.9% in the medical therapy group). At 1 year, the risk of major bleeding, major vascular complications, or stroke were higher in the TAVR group (22.3%, 16.8%, and 7.8%, respectively, in the TAVR group as compared to 11.2%, 2.2%, and 3.9%, respectively, in the medical therapy arm). All values were statistically significant [23] . In the 2-year follow-up of the PARTNER I cohort B study, the mortality benefit continued with 43.3% mortality in the TAVR arm and 68.0% mortality in the medical therapy arm at 2 years [26] .
During the same time period, 699 high-risk patients with severe aortic stenosis were randomized to undergo either TAVR or surgical AVR in the PARTNER I cohort A.
TAVR was performed either via the transfemoral route using the RetroFlex 3 delivery system or transapically in patients whose femoral vessels were too small to accommodate the RetroFlex 3 system. The study showed that TAVR was noninferior to surgical AVR in this patient population. The rates of death from any cause were 3.4% in the TAVR group and 6.5% in the surgical group at 30 days (P = 0.07), and 24.2% and 26.8%, respectively, at 1 year (P = 0.44). The rates of major stroke were not statistically significant at 30 days but were higher in the TAVR group at 1 year, 5.1% as compared to 2.4% in the surgical group (P = 0.07). At 30 days, major vascular complications were significantly more frequent with transcatheter replacement (11.0% vs.
3.2%); adverse events that were more frequent after surgical replacement included major bleeding (9.3% vs. 19.5%) and new-onset atrial fibrillation (8.6% vs. 16.0%). All values were statistically significant. Although more patients had improvement in their symptoms at 30 days in the TAVR arm, the two groups were found to be comparable at 1 year [24] . The 2-year outcomes of the cohort B patients showed a continued similarity between the two treatment arms with respect to mortality, reduction in symptoms, and improved valve hemodynamics, but increased paravalvular regurgitation in the TAVR arm, which was associated with increased late mortality [27] . The health-related quality of life for the patients in the PARTNER I trial was evaluated at 1 month, 6 months, and 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the 12-item Short Form-12 General Health Survey (SF-12). In the cohort B patients, TAVR resulted in significant improvements in health-related quality of life that were maintained for at least 1 year when compared to standard therapy [28] . The same analysis was done on the cohort A patients and it was found that health-related quality of life improved substantially between baseline and 1 year after either TAVR or AVR. TAVR via the transfemoral, but not the transapical route, was associated with a short-term advantage compared with surgery [29] .
In addition to the PARTNER I data from the US, there have been multiple reports of large registries from Europe and Canada using the Edwards SAPIEN valve [30] [31] [32] [33] [34] [35] . Although these results are not randomized, they offer real-world experience for TAVR performed at high-volume centers using the Edwards SAPIEN valve. The results of some of the major registries, as well as a summary of the PARTNER I results are outlined in Table 2 [24, 26, [30] [31] [32] [33] [34] [35] . Table 2 Results of large multicenter TAVR registries involving the Edwards SAPIEN THV 
COMPLICATIONS
The TAVR procedure is surrounded by several potential complications, partially because of the high-risk nature of the patient population and partially because of the invasiveness of the procedure itself. Major vascular complications were the most common complication seen in the PARTNER I trial. The risk was 11.0% compared to 3.2% in the surgical AVR arm (PARTNER I cohort A) [24] . However, with increased familiarity with the preclose technique, vascular complications can be virtually eliminated. If the preclose technique is unsuccessful, the cross-over balloon tamponade of anterograde flow will prevent any major bleeding, whilst also having a surgeon available to perform a cut-down and repair the arteriotomy site will expedite hemostasis. Covered stents can also be used; however, when they are inserted at a point of flexion (as in the common femoral artery) they are more prone to fracture. It will be interesting to see the rate of vascular complications in the PARTNER II data now that operators are more familiar with vascular closure techniques.
Stroke is the second most common complication following TAVR. In the PARTNER I cohort A patient population, the risk of stroke in TAVR arm at 30 days was 3.8% compared to 2.1% in the surgical arm (P = 0.2).
By 1 year, the risk of stroke in the TAVR arm had gone up to 5.1% compared to only 2.4% in the surgical arm (P = 0.07). Although these values
were not found to be statistically significant, the increased rate of stroke in the TAVR group is concerning. In this elderly patient population, the aortic arch is filled with calcium and atherosclerosis, and delivery of the large caliber valve across the arch can easily cause embolization. This issue is currently being addressed by designing smaller devices and delivery sheaths. There are also carotid protection devices that are under development to prevent embolization of debris in the brain.
Paravalvular leak (Fig. 5d) is another important complication of the TAVR procedure. In the 2-year follow-up of the PARTNER I trial, it was seen in 6.9% of the TAVR patients, compared to only 0.9% of the surgical AVR patients (P\0.001) and was associated with increased mortality [27] . To avoid paravalvular leak, it is important to position the valve centrally in the aortic annulus. The development of new THVs with better cuffs will hopefully improve this problem in the future. It has recently been shown that significant paravalvular leak following TAVR leads to increased morbidity and mortality. The Other complications reported in the PARTNER I trial include endocarditis and need for a permanent pacemaker, which were similar in both the TAVR and surgical groups [24] .
Coronary artery occlusion secondary to calcium embolization has been described and can usually be treated with emergent coronary artery stenting [18, 19] . Finally, valve embolization is a very rare but potentially devastating complication described in a few case reports [38] . When possible, the valve should be repositioned in the descending aorta and re-expanded there. If the valve embolizes into the LV, it needs to be removed surgically or transapically.
CURRENT USE
The Edwards SAPIEN THV is currently only FDAapproved for use in patients who satisfy the PARTNER I cohort B criteria, and who are 
FUTURE DIRECTIONS
CONCLUSION
The Edwards SAPIEN TAVR procedure can be performed safely and effectively for treatment of patients with severe symptomatic aortic stenosis. It is currently indicated for use in patients who are considered to be inoperable; however, in the future these indications may be expanded.
